Rushit Lodaya

With immune responses, from anti-PEG and ligand antibodies to component-linked immunogenicity, impacting LNP dosing regimens and limiting clinical success. This workshop will delve into advanced analytics for understanding safety and evaluate innovative solutions to achieve effective repeat dosing.

Topics include:

• Highlighting analytical strategies to pinpoint the cause of limited repeat dosing, are PEG, targeting ligands, ionizable lipids, or linkers are to blame?
• Uncovering PEG alternatives that offer the most promise for preserving circulation time and transfection efficiency while reducing immunogenicity
• Unleashing novel ionizable lipids, targeting ligands, and linker chemistries which degrade quickly, enhance endosomal escape and improve safety